Effectiveness, cost-utility, and benefits of a multicomponent therapy to improve the quality of life of patients with fibromyalgia in primary care: A mixed methods study protocol

Rosa Caballol Angelats, Alessandra Queiroga Gonçalves, Carina Aguilar Martín, Maria Cinta Sancho Sol, Gemma González Serra, Marc Casajuana, Noèlia Carrasco-Querol, José Fernández-Sáez, Maria Rosa Dalmau Llorca, Rosa Abellana, Anna Berenguera, SensiTEbre group, Rosa Caballol Angelats, Alessandra Queiroga Gonçalves, Carina Aguilar Martín, Maria Cinta Sancho Sol, Gemma González Serra, Marc Casajuana, Noèlia Carrasco-Querol, José Fernández-Sáez, Maria Rosa Dalmau Llorca, Rosa Abellana, Anna Berenguera, SensiTEbre group

Abstract

Introduction: Fibromyalgia (FM) is a chronic condition characterized by chronic pain, fatigue and loss of function which significantly impairs quality of life. Although treatment of FM remains disputed, some studies point at the efficacy of interdisciplinary therapy. This study aims to analyze the effectiveness, cost-utility and benefits of a multicomponent therapy on quality of life (main variable), functional impact, mood and pain in people suffering from FM that attend primary care centers (PCCs) of the Catalan Institute of Health (ICS).

Methods and analysis: A 2-phase, mixed methods study has been designed following Medical Research Council guidance. Phase 1: Pragmatic randomized clinical trial with patients diagnosed with FM that attend one of the 11 PCCs of the ICS Gerència Territorial Terres de l'Ebre. We estimate a total sample of 336 patients. The control group will receive usual clinical care, while the multicomponent therapy group (MT group) will receive usual clinical care plus group therapy (consisting of health education, exercise and cognitive-behavioural therapy) during 12 weeks in 2-hourly weekly sessions.

Analysis: the standardized mean response and the standardized effect size will be assessed at 3, 9, and 15 months after the beginning of the study using multiple linear regression models. Utility measurements will be used for the economic analysis. Phase 2: Qualitative socio constructivist study to evaluate the intervention according to the results obtained and the opinions and experiences of participants (patients and professionals). We will use theoretical sampling, with 2 discussion groups of participants in the multicomponent therapy and 2 discussion groups of professionals of different PCCs. A thematic content analysis will be carried out.

Ethics and dissemination: This study protocol has been approved by the Clinical Research Ethics Committee of the Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (code P18/068). Articles will be published in international, peer-reviewed scientific journals.

Trial registration: Clinical-Trials.gov: NCT04049006.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flowdiagram of the study. FIQR = Revised Fibromyalgia Impact Questionnaire, HADS = Hospital Anxiety and Depression Scale, MT group = multicomponent therapy group, SF-36 = Short Form 36 health survey questionnaire, VAS = visual analog scale.
Figure 2
Figure 2
Content of the multicomponent therapy sessions.

References

    1. Mas AJ, Carmona L, Valverde M, et al. Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain. Clin Exp Rheumatol 2008;26:519–26.
    1. Kevin C, Fleming MD, Volchek MM. Central sensitization syndrome and the initial evaluation of a patient with fibromyalgia: a review. Med J 2015;6:1–2.
    1. Fitzcharles MA, Ste-Marie PA, Pereira JX. Canadian Fibromyalgia Guidelines Committee. Fibromyalgia: evolving concepts over the past 2 decades. CMAJ 2013;185:E645–51.
    1. Wolfe F, Smythe HA, Yunus MB, et al. The American college of rheumatology 1990 criteria for the classification of fibromyalgia. report of the multicenter criteria committee. Arthritis Rheum 1990;33:160–72.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011;38:1113–22.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319–29.
    1. Marques AP, Santo A, Berssaneti AA, et al. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed 2017;57:356–63.
    1. Villanueva VL, Valía JC, Cerdá G, et al. Fibromialgia: diagnóstico y tratamiento. El estado de la cuestión. Rev Soc Esp Dolor 2004;11:430–43.
    1. Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009;11:R54.
    1. Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009;11:117.
    1. Brooks A, Hagen SE, Sathyanarayanan S, et al. Presenteeism: critical issues. J Occup Environ Med 2010;52:1055–67.
    1. Winkelmann A, Perrot S, Schaefer C, et al. Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study. Appl Health Econ Health Policy 2011;9:125–36.
    1. Feliu-Soler A, Borras X, Penarrubia-Maria MT, et al. Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study). BMC Complement Altern Med 2016;16:81.
    1. Busch AJ, Webber SC, Richards RS, et al. Resistance exercise training for fibromyalgia. Cochrane Database Syst Rev 2013. CD010884.
    1. Bernardy K, Klose P, Bush AJ, et al. Cognitive Behavioral therapies for fibromyalgia. Cochrane Database Syst Rev 2013. CD009796.
    1. Luciano JV, Guallar JA, Aguado J, et al. Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). Pain 2014;155:693–702.
    1. Giusti EM, Castelnuovo G, Molinari E. Differences in multidisciplinary and interdisciplinary treatment programs for fibromyalgia: a mapping review. Pain Res Manag 2017. 7261468.
    1. Ollevier A, Vanneuville I, Carron P, et al. A 12-week multicomponent therapy in fibromyalgia improves health but not in concomitant moderate depression, an exploratory pilot study. Disabil Rehabil 2019. 1–8.
    1. Martin J, Torre F, Padierna A, et al. Six-and 12-month follow-up of an interdisciplinary fibromyalgia treatment programme: results of a randomised trial. Clin Exp Rheumatol 2012;30:103–11.
    1. Saral I, Sindel D, Esmaeilzadeh S, et al. The effects of long- and short-term interdisciplinary treatment approaches in women with fibromyalgia: a randomized controlled trial. Rheumatol Int 2016;36:1379–89.
    1. Gelman SM, Lera S, Caballero F, et al. Tratamiento multidisciplinario de la fibromialgia. Estudio piloto prospectivo controlado. Rev Esp Reumatol 2005;32:99–105.
    1. Hauser W, Ablin J, Perrot S, et al. Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med 2017;127:47–56.
    1. Castel A, Fontova R, Montull S, et al. Efficacy of a multidisciplinary fibromyalgia treatment adapted for women with low educational levels: a randomized controlled trial. Arthritis Care Res (Hoboken) 2013;65:421–31.
    1. van Wilgen CP, Bloten H, Oeseburg B. Results of a multidisciplinary program for patients with fibromyalgia implemented in the primary care. Disabil Rehabil 2007;29:1207–13.
    1. Arnold LM, Gebke KB, Choy EH. Fibromyalgia: management strategies for primary care providers. Int J Clin Pract 2016;70:99–112.
    1. Stein KF, Miclescu A. Effectiveness of multidisciplinary rehabilitation treatment for patients with chronic pain in a primary health care unit. Scand J Pain 2013;4:190–7.
    1. Luciano JV, Martinez N, Penarrubia-Maria MT, et al. Effectiveness of a psychoeducational treatment program implemented in general practice for fibromyalgia patients: a randomized controlled trial. Clin J Pain 2011;27:383–91.
    1. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76:318–28.
    1. Goossens ME, Rutten-van Molken MP, Leidl RM, et al. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. Economic evaluation. J Rheumatol 1996;23:1246–54.
    1. Luciano JV, Sabes-Figuera R, Cardenosa E, et al. Cost-utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomized controlled trial. Clin J Pain 2013;29:702–11.
    1. Luciano JV, D’Amico F, Cerda-Lafont M, et al. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Res Ther 2014;16:451.
    1. Luciano JV, D’Amico F, Feliu-Soler A, et al. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus recommended drugs: an economic analysis alongside a 6-month randomized controlled trial conducted in Spain (EFFIGACT Study). J Pain 2017;18:868–80.
    1. Hedman-Lagerlof M, Hedman-Lagerlof E, Ljotsson B, et al. Cost-effectiveness and cost-utility of internet-delivered exposure therapy for fibromyalgia: results from a randomized, controlled trial. J Pain 2019;20:47–59.
    1. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. Int J Nurs Stud 2013;50:587–92.
    1. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008;337:a1655.
    1. Campbell M, Fitzpatrick R, Haines A, et al. Framework for design and evaluation of complex interventions to improve health. BMJ 2000;321:694–6.
    1. Centro Cochrane Iberoamericano y Agència de Qualitat i Avaluació Sanitàries de Catalunya. Evaluación y abordaje de la fibromialgia y el síndrome de fatiga crónica. Barcelona: Agència de Qualitat i Avaluació Sanitàries de Catalunya. Departament de Salut. Generalitat de Catalunya; 2017. Available at: Acessed August 23, 2019.
    1. Departament de Salut. Generalitat de Catalunya. Pla operatiu d’atenció a les persones afectades per les síndromes de senzibilització central: fibromiàlgia, síndrome de fatiga crònica i síndrome de sensibilitat química múltiple; 2016. Available at: Accessed August 23, 2019.
    1. Goldstein MG, Whitlock EP, DePue J. Multiple behavioral risk factor interventions in primary care. Summary of research evidence. Am J Prev Med 2004;27:61–79.
    1. Damschroder LJ, Lowery JC. Evaluation of a large-scale weight management program using the consolidated framework for implementation research (CFIR). Implement Sci 2013;8:51.
    1. Efron B. Forcing a sequential experiment to be balanced. Biometrika 1971;58:403–17.
    1. Alonso J, Prieto L, Anto JM. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 1995;104:771–6.
    1. Bennett RM, Friend R, Jones KD, et al. (FIQR): validation and psychometric properties. Arthritis Res Ther 2009;11:R120.
    1. Salgueiro M, Garcia-Leiva JM, Ballesteros J, et al. Validation of a Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR). Health Qual Life Outcomes 2013;11:132.
    1. Marques AP, Assumpcao A, Matsutani LA, et al. Pain in fibromyalgia and discrimination power of the instruments: visual analog scale, dolorimetry and the mcgill pain questionnaire. Acta Reumatol Port 2008;33:345–51.
    1. Crawford BK, Piault EC, Lai C, et al. Assessing fibromyalgia-related fatigue: content validity and psychometric performance of the Fatigue Visual Analog Scale in adult patients with fibromyalgia. Clin Exp Rheumatol 2011;29:S34–43.
    1. Sigal LH, Chang DJ, Sloan V. 18 tender points and the “18-wheeler” sign: clues to the diagnosis of fibromyalgia. JAMA 1998;279:434.
    1. Vallejo MA, Rivera J, Esteve-Vives J, et al. Use of the Hospital Anxiety and Depression Scale (HADS) to evaluate anxiety and depression in fibromyalgia patients. Rev Psiquiatr Salud Ment 2012;5:107–14.
    1. Cabrera V, Martín-Aragón M, Terol MC, et al. Hospital Anxiety and depression Scale (HADS) in fibromyalgia: sensitivity and specific analysis. Ter Psicol 2015;33:181–93.
    1. Departament de Salut. Generalitat de Catalunya. Guia per a l’avaluació de la fibromiàlgia i de la síndrome de fatiga crònic; 2017. Available at: Accessed August 23, 2019.
    1. Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 Health Survey. Lincoln, RI: QualityMetric Incorporated; 2000.
    1. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178–189.
    1. Belsley DA. Conditioning Diagnostics: Collinearity and Weak Data in regression. 1991;New York: John Wiley and Sons, 396p.
    1. Generalitat de Catalunya. Diari Oficial de la Generalitat de Catalunya; 2019. Available at: . Accessed August 23, 2019.
    1. Brownson R, Colditz G, Proctor E. Dissemination and Implementation Research in Health: Translating Science to Practice. 2012;New York: Oxford University Press, USA, 560p.
    1. Proctor EK, Landsverk J, Aarons G, et al. Implementation research in mental health services: an emerging science with conceptual, methodological, and training challenges. Adm Policy Ment Health 2009;36:24–34.
    1. Berenguera A, Fernández de Sanmamed MJ, Pons M, et al. Escuchar, observar y comprender, Recuperando la narrativa en las Ciencias de la Salud. Aportaciones de la investigación cualitativa. 2014;Barcelona: Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP J. Gol, 224p.
    1. Bourgault P, Lacasse A, Marchand S, et al. Multicomponent interdisciplinary group intervention for self-management of fibromyalgia: a mixed-methods randomized controlled trial. PLoS One 2015;10:e0126324.
    1. Ablin J, Fitzcharles MA, Buskila D, et al. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med 2013. 485272.
    1. Hauser W, Bernardy K, Arnold B, et al. Schiltenwolf M Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum 2009;61:216–24.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren